ducovest

SCPS:OTC-Scopus Biopharma Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.0004

Change

0.00 (0.00)%

Market Cap

USD 0.01M

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Company Website : https://scopusbiopharma.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
UCBJF UCB SA

N/A

 USD 35.87B
UCBJY UCB SA ADR

N/A

 USD 35.79B
ARGNF argenx SE

N/A

 USD 32.44B
GNMSF Genmab A/S

N/A

 USD 14.22B
WXIBF WuXi Biologics

N/A

 USD 10.26B
IVBIY IVBIY

N/A

 USD 10.24B
SBMFF Sino Biopharmaceutical Limited

N/A

 USD 8.56B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

 USD 8.48B
ZLDPF Zealand Pharma A/S

N/A

 USD 8.17B
WXXWY WuXi Biologics (Cayman) Inc

N/A

 USD 7.97B

ETFs Containing SCPS

IEO 18.57 % 0.42 %

N/A

 N/A
NRGD 10.00 % 0.00 %

N/A

 N/A
NRGU 10.00 % 0.00 %

N/A

 N/A
NRGO 10.00 % 0.00 %

N/A

 N/A
NRGZ 10.00 % 0.00 %

N/A

 N/A
YGRN 10.00 % 0.00 %

N/A

 N/A
IS0D:F iShares Oil & Gas Explora.. 9.69 % 0.00 %

N/A

 N/A
IOGP:LSE iShares Oil & Gas Explora.. 9.57 % 0.00 %

N/A

 N/A
SPOG:LSE iShares V Public Limited .. 9.57 % 0.00 %

N/A

 N/A
FRAK 8.73 % 0.54 %

N/A

 N/A
SXLE:LSE SPDR S&P U.S. Energy Sele.. 8.55 % 0.00 %

N/A

 N/A
ZPDE:F SPDR S&P U.S. Energy Sele.. 8.55 % 0.00 %

N/A

 USD 0.78B
IESU:LSE iShares S&P 500 Energy Se.. 7.46 % 0.00 %

N/A

 N/A
QDVF:F iShares S&P 500 Energy Se.. 7.39 % 0.00 %

N/A

 N/A
XUEN:F Xtrackers (IE) Public Lim.. 7.12 % 0.00 %

N/A

 USD 0.09B
IYE iShares U.S. Energy ETF 7.06 % 0.42 %

N/A

 N/A
XSEN:LSE db x-trackers MSCI USA En.. 6.91 % 0.00 %

N/A

 USD 0.08B
XUEN:LSE db x-trackers MSCI USA En.. 6.91 % 0.00 %

N/A

 USD 0.08B
JHME 6.90 % 0.48 %

N/A

 N/A
DDG 5.83 % 0.95 %

N/A

 N/A
DUG ProShares UltraShort Oil .. 5.83 % 0.95 %

N/A

 N/A
DIG ProShares Ultra Oil & Gas 5.75 % 0.95 %

N/A

 N/A
ERX Direxion Daily Energy Bul.. 4.99 % 1.08 %

N/A

 N/A
HPF:CA Energy Leaders Plus Incom.. 4.96 % 1.74 %

N/A

 N/A
ERYY 4.79 % 0.45 %

N/A

 N/A
WNRG:LSE SPDR MSCI World Energy UC.. 4.47 % 0.00 %

N/A

 N/A
XDW0:LSE db x-trackers MSCI World .. 4.46 % 0.00 %

N/A

 N/A
XDW0:F Xtrackers (IE) Public Lim.. 4.46 % 0.00 %

N/A

 USD 1.07B
HUL-U:CA 4.46 % 0.00 %

N/A

 N/A
HUL:CA 4.46 % 2.20 %

N/A

 N/A
IXC iShares Global Energy ETF 4.35 % 0.46 %

N/A

 N/A
IGE 4.32 % 0.46 %

N/A

 N/A
GASX 4.29 % 1.01 %

N/A

 N/A
FCG First Trust Natural Gas E.. 4.27 % 0.60 %

N/A

 N/A
NANR SPDR S&P® North American.. 3.28 % 0.35 %

N/A

 N/A
HEA-U:CA 2.61 % 0.00 %

N/A

 N/A
GASL 1.45 % 1.19 %

N/A

 N/A
TERM 0.88 % 0.64 %

N/A

 N/A
SCHJ Schwab 1-5 Year Corporate.. 0.09 % 0.00 %

N/A

 N/A
BWX SPDR® Bloomberg Internat.. 0.00 % 0.50 %

N/A

 N/A
EBND SPDR® Bloomberg Emerging.. 0.00 % 0.41 %

N/A

 N/A
ILF iShares Latin America 40 .. 0.00 % 0.48 %

N/A

 N/A
MTUM 0.00 % 0.15 %

N/A

 N/A
RYE 0.00 % 0.40 %

N/A

 N/A
WIP SPDR® FTSE International.. 0.00 % 0.50 %

N/A

 N/A
SMRU:LSE Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

 N/A
SM8T:F Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

 N/A
HPF-U:CA Harvest Energy Leaders Pl.. 0.00 % 0.00 %

N/A

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -99.07% 4% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.07% 4% F 1% F
Trailing 12 Months  
Capital Gain -99.18% 3% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.18% 3% F 1% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -66.82% 1% F N/A F
Dividend Return -66.82% 1% F N/A F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.52% 75% C 59% D-
Risk Adjusted Return -164.90% 2% F N/A F
Market Capitalization 0.01M 9% A- 4% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.